Compare MTA & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTA | MRVI |
|---|---|---|
| Founded | 1983 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.3M | 559.0M |
| IPO Year | 2017 | 2020 |
| Metric | MTA | MRVI |
|---|---|---|
| Price | $7.75 | $5.16 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $9.00 | $4.13 |
| AVG Volume (30 Days) | 486.5K | ★ 3.0M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | $81.63 | $12.54 |
| Revenue Next Year | $62.44 | $7.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.44 | $1.99 |
| 52 Week High | $9.25 | $5.00 |
| Indicator | MTA | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 59.79 | 71.36 |
| Support Level | $7.56 | $3.27 |
| Resistance Level | $7.74 | N/A |
| Average True Range (ATR) | 0.35 | 0.23 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 82.66 | 86.78 |
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company that engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests. Geographically, the company generates revenue from Australia, Brazil, Mexico, and the USA, with the majority generated from Brazil.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.